Denali Therapeutics (DNLI) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Zai Lab (ZLAB) over the past year, gaining 28.6% versus a loss of 23.0%. Over five years, DNLI leads with a -57.9% price change compared with -75.2% for ZLAB. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $2.70 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | ZLAB |
|---|---|---|
| Share price | $18.62 | $24.04 |
| Market cap | $2.98B | $2.70B |
| 1-day change | -2.82% | -5.02% |
| YTD return | +16.05% | +43.48% |
| 1-year return | +28.59% | -23.05% |
| 5-year return | -57.95% | -75.19% |
| EPS (TTM) | $-2.84 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $460.16M |
| Revenue growth (YoY) | — | +15.33% |
| Net income (latest FY) | $-512.54M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | — | -49.86% |
| Net margin | — | -38.15% |
| 52-week high | $27.30 | $33.65 |
| 52-week low | $13.75 | $15.96 |
| Distance from 52-week high | -31.79% | -28.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.66% | +37.85% |
| Average volume | 1.61M | 944.83K |
| Shares outstanding | 159.85M | 112.27M |
| Employees | 503 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed ZLAB by 51.6 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
DNLI vs ZLAB FAQ
Which is bigger, Denali Therapeutics or Zai Lab?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $2.70B for Zai Lab (ZLAB).
Which stock has performed better over the past year, DNLI or ZLAB?
DNLI returned +28.59% over the past 12 months, compared with -23.05% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Zai Lab in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Zai Lab.